Full Text 2014 Gynecologic Oncology Research and Practice Review: Updates on drug discovery in ovarian cancer
Introduction
In 2010, we published on recent advances in drug discovery for ovarian cancer
[1].
Since then, multiple drugs have either failed to advance into further
development, have newly been developed, or have demonstrated activity in
phase III trials. For example, with respect to bevacizumab, several
positive phase III trials have supported the use of this drug in upfront
and recurrent ovarian cancer cases yet FDA approval is pending. Another
example includes a 940 patient, phase III AGO-OVAR16 study which proved
advantageous in ovarian cancer treatment with pazopanib, increasing
median progression-free survival (PFS) by about 5.6 months
[2].
In addition, trabectedin was previously discussed and positive phase
III activity was reported, improving PFS, and overall response rate in a
672 patient study
[3].
Lastly, phase III results from the TRINOVA-1 trial of over 900 patients
found that trebananib (AMG 386) increased PFS as well as reduced
disease progression and death by 34% when combined with paclitaxel.
Unfortunately, several of the drugs previously described have been found
to be inactive, or with disappointing clinical outcomes. This review
will thus highlight new drugs for ovarian cancer that have recently
demonstrated positive phase II activity (Table
1).
The ultimate goal with this type of drug development is to achieve
prolonged remission and improved quality of life (QOL), for patients
with recurrent ovarian cancer.
0
comments
:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.